• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Chi-Med - Articles and news items

Expanded Phase II trial of savolitinib in NSCLC starts

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Savolitinib is a potential global first-in-class inhibitor of c-Met, an enzyme which has been shown to function abnormally in many types of solid tumours…

Chi-Med completes enrolment of its Phase III fruquintinib CRC trial

Industry news / 13 May 2016 / Victoria White, Digital Content Producer

FRESCO is a Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or metastatic colorectal cancer (CRC)…

Phase II trial of sulfatinib in thyroid cancer starts

Industry news / 2 March 2016 / Victoria White, Digital Content Producer

The trial will evaluate sulfatinib in locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer….

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +